Oh wow - thank you so much.

This, then, poses more questions... If GnRH agonists used in prostate cancer treatment might increase heart risks, and if research suggests that GnRH antagonists could be safer for the heart, but evidence is limited, and practical challenges like costs and additional drug risks complicate their use... how do I, as a normal bloke, even make sense of this - especially since it appears to me that (at least in my care circle) they appear to gloss over and overlook managing these risks during treatment.

It stands to reason, then, that the focus should shift to identifying and addressing heart risks when receiving hormone therapy, using better tools and prevention strategies. (and what would they be?) GnRH antagonists may benefit high-risk patients like me, but how do I balance effective cancer treatment with managing side effects, including heart risks? How do I even start to address this with the oncologist, who I assume is not thinking in this direction. Maybe I should provide the prescription and take my chance?